Belite Bio (BLTE) Depreciation & Amortization (CF) (2024 - 2025)
Belite Bio's (BLTE) quarterly Depreciation & Amortization (CF) came in at $45000.0 in Q4 2025, up 4.65% year-on-year from $43000.0 in Q4 2024, and up 4.65% quarter-over-quarter from $43000.0 in Q4 2024.
Belite Bio (BLTE) Depreciation & Amortization (CF) (2024 - 2025) Analysis & Trends
Belite Bio's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $45000.0 for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) rose 4.65% year-over-year to $45000.0 in Q4 2025; TTM through Mar 2026 was $45000.0, a 4.65% increase from a year earlier, with the FY2025 full-year figure at $464000.0, up 3.34% from the prior year.
- Depreciation & Amortization (CF) rose to $45000.0 in Q4 2025 per BLTE's latest filing, from $43000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $45000.0 in Q4 2025 and bottomed at $43000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45,000.00 |
| Dec 31, 2025 | 45,000.00 |
| Dec 31, 2024 | 43,000.00 |
| Dec 31, 2024 | 43,000.00 |